Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion

European Journal of Ophthalmology

Volumn 15, Issue 6, 2005, Pages 751-758

  Jonas, Jost B ^a,b   Akkoyun, I ^a   Kamppeter, B ^a   Kreissig, I ^a   Degenring, R F ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Central retinal vein occlusion; Cystoid macular edema; Intraocular pressure; Intravitreal triamcinolone; Iris neovascularization; Secondary angle closure glaucoma; Steroid response

Indexed keywords

NEOMYCIN; POLYMYXIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VISUAL ACUITY;

EID: 29244447509     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500615     Document Type: Article

References (46)

1. Hayreh SS, Klugman MR, Podhajsky P, et al. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefes Arch Clin Exp Ophthalmol 1990; 228: 281-96.
2. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology 1995; 102: 1425-33.
3. Hayreh SS. Management of central retinal vein occlusion. Ophthalmologica 2003; 217: 167-88.
4. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425-7.
5. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920-7.
6. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone acetonide for diabetic macular oedema. Arch Ophthalmol 2003; 121: 57-61.
7. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular oedema: an optical coherence tomography study. Ophthalmology 2001; 108: 765-72.
8. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular oedema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001; 119: 1380-3.
9. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29: 2-6.
10. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular oedema. Am J Ophthalmol 2003; 135: 246-9.
11. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular oedema. J Cataract Refract Surg 2003; 29: 27-33.
12. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular oedema. Am J Ophthalmol 2003; 136: 384-6.
13. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative and angiogenic diseases. Prog Retin Eye Res 2005 (in press).
14. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 1998; 26: 277-81.
15. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal trimcinolone. A pilot study. Aust NZ J Ophthalmol 1995; 23: 293-8.
16. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431-2.
17. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-50.
18. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002; 240: 873-4.
19. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003; 87: 462-8.
20. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-71.
21. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001; 10: 284-7.
22. Jonas JB, Söfker A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularisation. J Cataract Refract Surg 2002; 28: 2040-1.
23. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064-7.
24. Jonas JB, Söfker A, Hayler J, Degenring RF. Intravitreal crystalline triamcinolone acetonide as additional tool in pars plana vitrectomy for complicated proliferative vitreo-retinopathy? Acta Ophthalmol 2003; 81: 663-5.
25. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graefes Arch Clin Exp Ophthalmol 2001; 239: 464-5.
26. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment of chronic uveitis. Br J Ophthalmol 2003; 87: 361.
27. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979; 77: 171-80.
28. Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina 1996; 16: 166-7.
29. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000; 20: 554-5.
30. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247-8.
31. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular oedema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 782-3.
32. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular oedema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136: 419-25.
33. Ip M, Kahana A, Altaweel M. Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Semin Ophthalmol 2003; 18: 67-73.
34. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004; 137: 758-60.
35. Chen SD, Lochhead J, Patel CK, Frith P. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol 2004; 88: 154-5.
36. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. Retina 2004; 24: 324-7.
37. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal re-injection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122: 218-22.
38. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41: 3569-75.
39. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-9.
40. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000; 121: 458-65.
41. McCuen BW 2nd, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91: 785-8.
42. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101: 190-5.
43. ivilcim M, Peyman GA, El-Dessouky ES, et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000; 31: 474-8.
44. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992; 110: 259-66.
45. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-7.
46. Spandau UHM, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage-dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular edema. Br J Ophthalmol 2005 (in press).